Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3833-3837

  Takahashi, Hideto ^a   Kurishima, Koichi ^a   Ishikawa, Hiroichi ^b   Kagohashi, Katsunori ^a   Kawaguchi, Mio ^a   Satoh, Hiroaki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

Author keywords

CYFRA21 1; Cytokeratin; Non small cell lung cancer; Prognosis; Survival; Tumour marker

Indexed keywords

CYTOKERATIN 19 FRAGMENT; TUMOR MARKER; ANTIGEN CYFRA21.1; CYTOKERATIN 19; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; BLOOD; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATIN-19; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77958579217     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T and Ichinose Y: Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 47: 85-91, 2005. (Pubitemid 39643245)
2. Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M and Hizawa N: Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res 27: 4457-4460, 2007.
3. Coulombe PA: The cellular biology of keratins: beginning a new era. Curr Opin Cell Biol 5: 17-29, 1993.
4. Iyonaga K, Miyajima M, Suga M, Saita N and Ando M: Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissue from patients with idiopathic pulmonary fibrosis. J Pathol 182: 217-224, 1997. (Pubitemid 27287845)
5. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Jaroszewicz E and Laudanski J: Evaluation of CYFRA 21-1 as a new marker for non-small cell lung cancer. Eur J Cancer Prev 3: 227-230, 1994. (Pubitemid 24142424)
6. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H and Quoix E: Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 108: 163-169, 1995.
7. Szturmowicz M, Sakowicz A, Rudzinski P, Zych J, Wiatr E, Zaleska J and Rowinska-Zakrzewska E: The clinical value of Cyfra 21-1 estimation for lung cancer patients. Int J Biol Markers 11: 172-177, 1996. (Pubitemid 26373599)
8. Bréchot JM, Chevret S, Nataf J, Le Gall C, Frétault J, Rochemaure J and Chastang C: Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33: 385-391, 1997.
9. Niklinski J, Burzykowski T, Niklinska W, Laudanski J, Chyczewski L, Rapellino M and Furman M: Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 12: 1424-1428, 1998. (Pubitemid 29011441)
10. Pujol JL, Boher JM, Grenier J and Quantin X: Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-231, 2001.
11. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheid HH, Broermann P, Berdel WE, Macha HN and Thomas M: Prognostic impact of CYFRA21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36: 265-270, 2002. (Pubitemid 34497125)
12. Kulpa J, Wójcik E, Reinfuss M and Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48: 1931-1937, 2002.
13. Muley T, Dienemann H and Ebert W: Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 23: 4085-4093, 2003.
14. Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F and Kleisbauer JP: Prognostic value of combination of CYFRA21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 98: 357-362, 2004.
15. Merle P, Janicot H, Filaire M, Roux D, Bailly C, Vincent C, Gachon F, Tchirkov A, Kwiatkowski F, Naamé A, Escande G, Caillaud D and Verrelle P: Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients. Int J Biol Markers 19: 310-315, 2004.
16. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T and Grenier J: CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90: 2097-2105, 2004. (Pubitemid 38869712)
17. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F and Paganuzzi M: Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non-small cell lung cancer. Cancer 107: 2842-2849, 2006. (Pubitemid 44937038)
18. Suzuki H, Ishikawa S, Satoh H, Ishikawa H, Sakai M, Yamamoto T, Onizuka M and Sakakibara Y: Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg 32: 648-652, 2007. (Pubitemid 47362711)
19. Crowley J, LeBlanc M, Jacobson J and Salmon S: Some exploratory tools for survival analysis. In: Lecture Notes on Statistics. Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. New York: Springer, 199-229, 1997.
20. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
21. Passlick B: Micrometastases in non-small cell lung cancer (NSCLC). Lung Cancer 34(Suppl 3): S25-9, 2001.
22. Ohara G, Satoh H and Hizawa N: Prognostic markers for stage I non-small cell lung cancer. Lung Cancer 59: 137, 2008.
23. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M and Sekizawa K: Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 9: 581-583, 2002.